Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis

被引:0
|
作者
Bhatia, Neal [1 ]
Gold, Linda Stein [2 ]
Kircik, Leon H. [3 ,4 ,5 ,6 ,7 ]
Schreiber, Rhonda [8 ]
机构
[1] Therapeut Clin Res, San Diego, CA 92161 USA
[2] Henry Ford Hlth Syst, Detroit, MI USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA
[5] Phys Skin Care PLLC, Louisville, KY USA
[6] DermResearch PLLC, Louisville, KY USA
[7] Skin Sci PLLC, Louisville, KY USA
[8] Mayne Pharma LLC, Raleigh, NC USA
关键词
OINTMENT; CREAM;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations. Objective:To determine the safety and effectiveness of HBP-Foam in subjects with plaque psoriasis. Methods: Two randomized, double-blind, vehicle-controlled clinical studies were conducted in 560 adult subjects with moderate to severe plaque psoriasis. Subjects applied the assigned test article to all psoriatic plaques twice daily for 14 days. The key efficacy measures were the proportion of subjects with "treatment success," defined as those subjects that achieved a score of 0 (clear) or 1 (almost clear) and at least a two-grade improvement compared to baseline for the Investigator's Global Assessment (IGA) and for the clinical signs of psoriasis (plaque elevation, scaling, and erythema) as well as pruritus. Safety measurements included adverse events and local skin reactions in the treatment area. Results: HBP-Foam was statistically superior to vehicle in achieving "Treatment Success" in 25.3% and 30.7% vs 3.9% and 74% (P<0.001) in Studies 1 and 2, respectively. Pruritus scores statistically improved by over 30% in HBP-Foam treated subjects. In addition, these subjects experienced a significant reduction in the clinical signs of psoriasis (plaque elevation, scaling, and erythema). In contrast, in the vehicle groups the decrease in psoriasis-related signs was generally not observed. Safety outcomes were unremarkable and similar in both the HBP-Foam and vehicle treatment groups. Conclusions:These results demonstrate the safety and effectiveness of HBP-Foam in the treatment of plaque psoriasis. Furthermore, this novel foam formulation has demonstrable for its ease of application over large and/or hairy treatment areas.
引用
收藏
页码:790 / 796
页数:7
相关论文
共 50 条
  • [31] Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate-to-Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study
    Feldman, Steven R. R.
    Kay, Richard
    Reznichenko, Nataliya
    Sobierska, Joanna
    Dias, Roshan
    Otto, Hendrik
    Haliduola, Halimu N. N.
    Sattar, Abid
    Ruffieux, Ruth
    Stroissnig, Heimo
    Berti, Fausto
    BIODRUGS, 2023, 37 (04) : 551 - 567
  • [32] Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
    Philipp, Thomas
    Smith, Timothy R.
    Glazer, Robert
    Wernsing, Margaret
    Yen, Joseph
    Jin, James
    Schneider, Helmut
    Pospiech, Rainer
    CLINICAL THERAPEUTICS, 2007, 29 (04) : 563 - 580
  • [33] Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study (vol 189, pg 33, 2023)
    Landis, Megan N.
    Smith, Stacy R.
    Berstein, Gabriel
    Fetterly, Gerald
    Ghosh, Pranab
    Feng, Gang
    Pradhan, Vivek
    Aggarwal, Sudeepta
    Banfield, Christopher
    Peeva, Elena
    Vincent, Michael S.
    Beebe, Jean S.
    Tarabar, Sanela
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (05) : E81 - E81
  • [34] Second Multicenter, Randomized, Double-blind, Parallel-group Evaluation of Effectiveness and Safety of Intravesical Sodium Chondroitin Sulfate Compared With Inactive Vehicle Control in Subjects With Interstitial Cystitis/Bladder Pain Syndrome EDITORIAL COMMENT
    Agarwal, Mayank Mohan
    UROLOGY, 2012, 79 (06) : 1224 - 1225
  • [35] A novel aerosol foam formulation of calcipotriene (Cal) 0.005% plus betamethasone dipropionate (BD) 0.064% is more efficacious than Cal and BD foam alone in treating psoriasis vulgaris: A randomized, double-blind, multicenter, three-arm, phase II study
    Lebwohl, Mark
    Tyring, Stephen
    Bukhalo, Michael
    Alonso-Llamazares, Javier
    Olesen, Martin
    Lowson, David
    Yamauchi, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB222 - AB222
  • [36] Secukinumab compared with placebo and Etanercept: The first 52-week head-to-head comparison of two biologics in a randomized, double-blind phase 3 study in subjects with moderate-to-severe plaque psoriasis (FIXTURE)
    Spelman, L.
    Langley, R.
    Reich, K.
    Griffiths, C.
    Puig, L.
    Zaldivar, E. Rivas
    Wasel, N.
    Salko, T.
    Notter, M.
    Helou, S.
    Papavassilis, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 52 - 52
  • [37] Secukinumab compared with placebo and etanercept: The first 52-week head-to-head comparison of two biologics in a randomized, double-blind phase 3 study in subjects with moderate-to-severe plaque psoriasis (FIXTURE)
    Langley, R.
    Reich, K.
    Griffiths, C.
    Puig, L.
    Spelman, L.
    Zaldivar, E. Rivas
    Wasel, N.
    Salko, T.
    Notter, M.
    Helou, S.
    Papavassilis, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 14 - 14
  • [38] Rationale and design of the MODIFY study: A phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease
    Wanner, Christoph
    Hughes, Derralynn
    Kimonis, Virginia
    Politei, Juan
    Uceyler, Nurcan
    Warnock, David G.
    Cornelisse, Peter
    Frey, Aline
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S159 - S159
  • [39] DOSE-RANGE FINDING STUDY OF TELENZEPINE (1,5 VS 3 VS 5 MG ONCE DAILY) IN ACUTE DUODENAL-ULCER THERAPY - A RANDOMIZED, DOUBLE-BLIND MULTICENTER PARALLEL-GROUP COMPARISON
    HUTTEMANN, W
    SCHNEIDER, A
    MEDIZINISCHE KLINIK, 1989, 84 (12) : 574 - 577
  • [40] A phase II randomized, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of three strengths of ad 452 in adult subjects with active rheumatoid arthritis
    Sheitanov, Y.
    Povoroznyuk, V.
    Dimic, A.
    Bookbinder, S.
    George, M.
    Gauler, G.
    von Hinuber, U.
    Walker, D.
    Braun, J.
    Fear, S.
    Fritchley, S.
    Tansley, R.
    Baker, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 448 - 448